Clinical Trial Update: Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg [Phase 3]

View source ↗

Summary

A single-arm Phase 3 trial evaluating valoctocogene roxaparvovec at 4e13 vg/kg in Hemophilia A has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Valoctocogene roxaparvovec (valoctocogene roxaparvovec)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2021-10-08